HCPCS Level II code J1449 designates the injectable biologic eflapegrastim-xnst, reported per 0.1 mg. Eflapegrastim is a long-acting granulocyte colony-stimulating factor used to reduce febrile neutropenia risk in patients receiving myelosuppressive chemotherapy; having a distinct HCPCS code enables accurate billing, utilization tracking, and coverage determinations across payers. Nationally, biologic supportive care agents like eflapegrastim factor into oncology care pathways and drug cost management, making this code relevant for providers, payers, and policy analysts.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical role and service context, typical sites of administration, and the scope of payers that commonly adjudicate claims for this agent. The publication also outlines where to expect benchmarking information, policy updates, and clinical context to inform coding, billing, and coverage conversations. Data elements that were not provided in the input are noted as unavailable; the summary focuses on national implications rather than state-specific policy.

What readers will learn:

• The clinical and billing identity of HCPCS Level II code J1449 and its role in supportive oncology care
• Which major payers are typically involved in coverage and adjudication
• The types of benchmarks and policy updates that affect billing and utilization of injectable G-CSF agents